The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients
Crossref DOI link: https://doi.org/10.1186/s13737-016-0031-6
Published Online: 2016-01-28
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zaltzman, Alina S. R
Glick, Lauren A.
Zaltzman, Jeffrey S.
Nash, Michelle
Huang, Michael
Prasad, G. V. Ramesh
Funding for this research was provided by:
Astellas Pharma US
